Abstract: Positron emitting radionuclides are used to label different compounds, allowing the study of the major biological systems using PET (positron emission tomography) imaging. Although there are several radionuclides suited for PET imaging, routine clinical applications are still based on a restrict group constituted by 18 F, 11 C, and, more recently, 68 Ga. However, with the enlarged availability of low-energy cyclotrons and technical improvements in radionuclide production, the use of unconventional radionuclides is progressively more common. Several examples of unconventional radionuclides for PET imaging are being suggested, and 45 Ti could be suggested as a model, due to its interesting properties such as its abundant positron emission (85%), reduced positron energy (β + endpoint energy = 1040 keV), physical half-life of 3.09 h, and interesting chemical properties. This review aims to introduce the role of cyclotrons in the production of unconventional radionuclides for PET imaging while using 45 Ti as an example to explore the potential biomedical applications of those radionuclides in PET imaging.
Introduction: Unconventional Radionuclides for PET Imaging
The incorporation and utilization of technological developments in clinical routine is becoming normal in modern practice of medicine. The application of imaging modalities is improving the quality of medical care and procedures that are available in medicine, which is an attitude that enhances the rapid implementation of modern paradigms of evidence-based medicine and science-based medicine. In fact, medical imaging occupies a primary position in clinical decision algorithms. In such context, non-invasive imaging modalities could allow for accurate diagnoses, increase precision in treatment choice/planning, and provide opportunities to follow the evolution of the clinical status of patients [1] . These modalities could also act over wide ranges of time and size scales involved in biological and pathological processes. Multiple imaging techniques are available, including X-ray imaging, computerized tomography (CT), magnetic resonance (MR) imaging, ultrasonography (US), Table 1 . Some unconventional positron emission tomography (PET) radionuclides and corresponding physical properties [13] .
Radionuclide
Half-Life β + Endpoint Energy (MeV) 44 As already cited, conventional applications of PET imaging are based on organic elements with short half-lives (minutes to hours). A careful analysis of the radionuclides listed in Table 1 shows a tendency to explore radionuclides with higher physical half-lives and chemical characteristics associated with metallic elements (inorganic elements). In fact, the use of nuclides of inorganic elements has been studied since the discovery of radioactivity, but nuclear properties are principal factors that justify the development of the new compounds, while the availability of radionuclides in high specific activities and inorganic chemistry issues at the radiotracer level are the most frequent challenges [14] . Even so, unconventional radiometals are gradually being introduced, diversifying the available tools and procedures in nuclear medicine, particularly in PET imaging.
Cyclotrons and the Production of Unconventional Radionuclides
Today, more than 2700 radionuclides have been produced artificially with particle accelerators [15] . In addition, a few examples are also being obtained in loco using radionuclide generators through radioactive decay.
PET radionuclides, in particular, can be produced in cyclotrons, especially using inducing (p,n) nuclear reactions in the targets of stable isotopes.
Routine cyclotron production processes are made possible by the actual dissemination of these devices. As a matter of fact, by the end of 2005, there were 262 cyclotrons operating in the 39 member states of International Atomic Energy Agency (IAEA); however, it was believed that around 350 cyclotrons were operating in the whole world, according to a database of the agency [16] . Unfortunately, there is no official update of this report, because it is not easy to correctly estimate the number of cyclotrons operating nowadays all over the world.
The commercially available cyclotrons can be classified with respect to the particle type and maximum energy reached, the method of ion production, the technique of beam extraction from the cyclotron (or absence of extraction), the intensity of the accelerated ion beams, and other specific properties or features [17, 18] . There are different classifications based on the type and energy of the accelerated particles [17, 19] . Independently from the classification used, an important aspect to mention is that near 70% of the cyclotrons disseminated over the world are low-energy cyclotrons (≤20 MeV) [16] .
According to empirical and practical evidence, the cyclotrons that typically have been applied worldwide in radionuclide production comprise properties such as: (i) the capability of accelerating negative ions (H − ); (ii) beam extraction using stripper foils; (iii) fixed beam energy between 10-18 MeV, or 10-24 MeV mainly if the installation is intended for the production of many radionuclides, large-scale production and/or research purposes; (iv) fixed frequency of the RF generator; (v) two or four dees placed in valleys; (vi) internal ion source(s); (vii) the possibility of adjusting the beam position on the target; (viii) possibility of multi-target irradiations; (ix) compact radiation shielding around the device ("self-shielded" cyclotron); and (x) a high level of automation and simplicity in maintenance.
Despite the existence of the formal classifications, cyclotrons that respect the criteria stated in the last paragraph are normally classified by professionals of the field as "small cyclotrons", "low-energy cyclotrons" or even as "medical cyclotrons", and are applied to induce (p,n) reactions, which are typically low-energy processes with a constant onset below 9 MeV [20] .
After the careful optimization of technical details such as targetry and irradiation parameters, high production yields of some of the unconventional radionuclides covered in this paper have been obtained in cyclotrons [21] [22] [23] [24] [25] [26] . Examples of such radionuclides and recommended nuclear reactions are given in Table 2 . As more research studies in radionuclide production are delivered with successful results, which are conjugated with promising results in the preclinical and clinical trials that are currently being developed, these "unconventional" radionuclides are set to play an increasingly important role in nuclear medicine. These considerations highlight the pivotal role that cyclotrons have in solving the availability issues of interesting radionuclides for PET imaging [21] .
Titanium-45 and Its Applications
Among the different examples that could be used to explore the paradigm of unconventional radionuclides for PET imaging in analysis, 45 Ti is an interesting case study.
The nuclide 45 Ti has a half-life of 3.09 h, which allows for distribution within a broader region than radiopharmaceuticals based on 18 F or other shorter half-life radionuclides. On the other hand, its decay is predominantly based on positron emission (85%), with a maximum positron energy of 1040 keV and an average energy of 439 keV, which assures good image quality in PET images.
Preliminary results that were obtained in the experimental program of our group revealed the production feasibility of 45 Ti in low-energy cyclotrons through the use of a 45 Sc(p,n) 45 Ti nuclear reaction, with proton beams higher than 3 MeV. The maximum cross-section values were determined for proton beams with energy in the range between 10-14 MeV, while significant impurities production was found for energies higher than 17 MeV (see Table 3 ). These results mean that the development of a routine production process is possible, and research on the subject is ongoing [27] . Table 3 . Preliminary results of experimental cross-section values for 45 Sc(p,n) 45 Ti nuclear reaction.
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In addition, the chemical properties of Ti allow two different scenarios for developing radiopharmaceuticals: (i) the "direct" labeling of ligands using chelation chemistry and/or simple covalent bounds with ligands of interest; or (ii) radiolabeled nanoparticles (either to label nanoparticles that are already explored in the field of nuclear medicine, or to label titanium oxide nanoparticles that could be relevant for clinical purposes).
The first reference to a potential application of 45 Ti belongs to a Japanese research team, and was published in 1981 by the Cyclotron and Radionuclide Center (CYRIC) of Tokohu University [28] .
This group simultaneously evaluated the production, target chemistry (extraction and purification of 45 Ti), and radiochemistry (labeling), and conducted some animal experiments. The main conclusion was centered on the potential of 45 Ti-compounds to become "a new series of the positron-emitting radiopharmaceutical", even considering some problems related to the stability of 45 TiCl 4 [28] . Examples of 45 Ti-phytate and 45 Ti-DTPA images are shown in Figure 1 .
Some years later, the same group reported the use of other 45 Ti-labeled compounds, namely 45 TiOCl 2 and 45 TiO-phytate, as potential colloid agents for imaging the reticuloendothelial system.
They also indicated 45 Ti-DTPA (diethylenetriaminepentaacetic), 45 Ti-citrate, and 45 Ti-HSA (human serum albumin) as possible agents for estimating blood volume and indicators of the breakdown of the blood-brain barrier [29] .
Considering the beginning of the study on the pathway of incorporation of titanium-based anticancer drugs such as budotitane(C 24 H 28 O 6 Ti), 45 Ti-budotitane was prepared and incorporated into liposomes to provide optimal tumor targeting [30] . Apart from this work, no further experimental studies were found on biodistribution or imaging using this compound. Some years later, the same group reported the use of other 45 Ti-labeled compounds, namely 45 TiOCl2 and 45 TiO-phytate, as potential colloid agents for imaging the reticuloendothelial system. They also indicated 45 Ti-DTPA (diethylenetriaminepentaacetic), 45 Ti-citrate, and 45 Ti-HSA (human serum albumin) as possible agents for estimating blood volume and indicators of the breakdown of the blood-brain barrier [29] .
Considering the beginning of the study on the pathway of incorporation of titanium-based anticancer drugs such as budotitane(C 24 H 28 O 6 Ti), 45 Ti-budotitane was prepared and incorporated into liposomes to provide optimal tumor targeting [30] . Apart from this work, no further experimental studies were found on biodistribution or imaging using this compound. 45 Ti-phytate (A) and 45 Ti-DTPA (diethylenetriaminepentaacetic) (B) acquired 10 minutes (A1 and B1) and 60 minutes (A2 and B2) after injection in rats. Images published by Ishiwata et al. in 1981 [28] .
After a gap of some years, Vavere et al. [31] reported an evaluation study of 45 Ti as a radionuclide for PET imaging. Despite other considerations, it was reported that the cyclotron production and purification of 45 Ti is feasible. The work also demonstrated a clear spatial resolution observed down to a rod diameter of 1.25 mm using a Derenzo phantom, i.e., a resolution comparable with 18 F, only with a slight degradation due to the higher energy endpoint and consequent range widening of positrons emitted by 45 Ti (see Figure 2) [31]. Another study of Vavere and Welch [32] produced 45 Ti and used small animal imaging with 45 Ti-transferrin, which provided new insights about the mechanism of action of a new class of cytostatic agents based on titanium complexes. This research performed a direct labeling of apotransferrin with 45 Ti and studied the resultant biodistribution. The microPET images provided indications on the increased uptake of 45 Ti-transferrin in tumors, with retention up to 24 h, demonstrating that titanium radiopharmaceuticals could be explored as new tools for the in vivo 45 Ti-phytate (A) and 45 Ti-DTPA (diethylenetriaminepentaacetic) (B) acquired 10 minutes (A1 and B1) and 60 minutes (A2 and B2) after injection in rats. Images published by Ishiwata et al. in 1981 [28] .
After a gap of some years, Vavere et al. [31] reported an evaluation study of 45 Ti as a radionuclide for PET imaging. Despite other considerations, it was reported that the cyclotron production and purification of 45 Ti is feasible. The work also demonstrated a clear spatial resolution observed down to a rod diameter of 1.25 mm using a Derenzo phantom, i.e., a resolution comparable with 18 F, only with a slight degradation due to the higher energy endpoint and consequent range widening of positrons emitted by 45 Ti (see Figure 2) [31] . Some years later, the same group reported the use of other 45 Ti-labeled compounds, namely 45 TiOCl2 and 45 TiO-phytate, as potential colloid agents for imaging the reticuloendothelial system. They also indicated 45 Ti-DTPA (diethylenetriaminepentaacetic), 45 Ti-citrate, and 45 Ti-HSA (human serum albumin) as possible agents for estimating blood volume and indicators of the breakdown of the blood-brain barrier [29] .
After a gap of some years, Vavere et al. [31] reported an evaluation study of 45 Ti as a radionuclide for PET imaging. Despite other considerations, it was reported that the cyclotron production and purification of 45 Ti is feasible. The work also demonstrated a clear spatial resolution observed down to a rod diameter of 1.25 mm using a Derenzo phantom, i.e., a resolution comparable with 18 F, only with a slight degradation due to the higher energy endpoint and consequent range widening of positrons emitted by 45 Ti (see Figure 2) [31]. Another study of Vavere and Welch [32] produced 45 Ti and used small animal imaging with 45 Ti-transferrin, which provided new insights about the mechanism of action of a new class of cytostatic agents based on titanium complexes. This research performed a direct labeling of apotransferrin with 45 Ti and studied the resultant biodistribution. The microPET images provided indications on the increased uptake of 45 Ti-transferrin in tumors, with retention up to 24 h, demonstrating that titanium radiopharmaceuticals could be explored as new tools for the in vivo Another study of Vavere and Welch [32] produced 45 Ti and used small animal imaging with 45 Ti-transferrin, which provided new insights about the mechanism of action of a new class of cytostatic agents based on titanium complexes. This research performed a direct labeling of apotransferrin with 45 Ti and studied the resultant biodistribution. The microPET images provided indications on the increased uptake of 45 Ti-transferrin in tumors, with retention up to 24 h, demonstrating that titanium radiopharmaceuticals could be explored as new tools for the in vivo imaging of tumors [31] . This data also supports the use of 45 Ti-labeled compounds in theranostics and personalized medicine, taking the ability to select patients for a specific type of treatment into account.
However, Price et al. [33] published a work reporting some problems regarding the purification of 45 Ti to be used in the radiolabeling process of transferrin. They reported losses of up to 53% of the 45 Ti activity in the waste fractions during the separation process. However, it seems to be a problem with this particular experiment, because other authors have achieved good radiochemical yields in the labeling of proteins such as transferrin or Df-antibody [34] .
In general, the reappearance of titanium-based drugs to treat cancer has been met with some success. The several chemical steps that are needed to stabilize these new titanium-based antineoplastics are being developed. In this research, the ligand salan seems to play a special role and lead to a significant investment in the development of these titanium-based drugs [35, 36] . However, it is also known that the phase of drug development represents a highly complex, inefficient and costly process that usually takes huge amounts of time and money. Again, nuclear medicine imaging can be decisive, enhancing the efficiency of selecting the candidate drugs that should move forward into clinical trials or be abandoned [37] . The conjugation of the need for more information about drug pharmacokinetics, and the added value of nuclear medicine in the drug development process, can be used strategically; 45 Ti labeling of compounds of interest could boost the research on titanium-based drugs. In fact, this conceptual idea is not totally original, because already published data shows the use of 45 Ti-salan compounds as translational tools to help these drugs in the passage from fundamental research to clinical applications (example in Figure 3 ) [38] . imaging of tumors [31] . This data also supports the use of 45 Ti-labeled compounds in theranostics and personalized medicine, taking the ability to select patients for a specific type of treatment into account. However, Price et al. [33] published a work reporting some problems regarding the purification of 45 Ti to be used in the radiolabeling process of transferrin. They reported losses of up to 53% of the 45 Ti activity in the waste fractions during the separation process. However, it seems to be a problem with this particular experiment, because other authors have achieved good radiochemical yields in the labeling of proteins such as transferrin or Df-antibody [34] .
In general, the reappearance of titanium-based drugs to treat cancer has been met with some success. The several chemical steps that are needed to stabilize these new titanium-based antineoplastics are being developed. In this research, the ligand salan seems to play a special role and lead to a significant investment in the development of these titanium-based drugs [35, 36] . However, it is also known that the phase of drug development represents a highly complex, inefficient and costly process that usually takes huge amounts of time and money. Again, nuclear medicine imaging can be decisive, enhancing the efficiency of selecting the candidate drugs that should move forward into clinical trials or be abandoned [37] . The conjugation of the need for more information about drug pharmacokinetics, and the added value of nuclear medicine in the drug development process, can be used strategically; 45 Ti labeling of compounds of interest could boost the research on titanium-based drugs. In fact, this conceptual idea is not totally original, because already published data shows the use of 45 Ti-salan compounds as translational tools to help these drugs in the passage from fundamental research to clinical applications (example in Figure 3 ) [38] . However, the concept can be even taken further, if one hypothesizes that 45 Ti compounds could act as diagnostic imaging agents of the same cancers that could be hereafter treated with titanium-based drugs. This once again suggests a role for 45 Ti in theranostics and personalized medicine.
In the paradigm of personalized medicine, nanoparticles are being studied as drug delivery systems, and their application as vectors for radionuclide-based molecular imaging is a powerful tool of growing interest [39] . Indeed, in another context, recent data suggests that functionalized However, the concept can be even taken further, if one hypothesizes that 45 Ti compounds could act as diagnostic imaging agents of the same cancers that could be hereafter treated with titanium-based drugs. This once again suggests a role for 45 Ti in theranostics and personalized medicine.
In the paradigm of personalized medicine, nanoparticles are being studied as drug delivery systems, and their application as vectors for radionuclide-based molecular imaging is a powerful tool of growing interest [39] . Indeed, in another context, recent data suggests that functionalized titanium dioxide nanoparticles (TiO 2 ) can be surface-engineered to target cancer cells [40] [41] [42] [43] [44] . Thus, the radiolabeling of TiO 2 nanoparticles with 45 Ti could constitute a tool to provide in vitro biodistribution studies, which can also allow the in vivo monitoring of its biological distribution and the pharmacokinetics of such drug delivery systems. The nanoparticle radiolabeling could be achieved by different methodologies, including activation methods and synthesis based on radioactive precursors [45] . However, apart from other advantages related to the specific activity obtained, synthesis based on radioactive precursors appears to be the simplest and most favorable option, mainly due to the coincidence between the nanoparticle chemical nature (titanium) and the radionuclide that is aimed to be used for radiolabeling ( 45 Ti). Figure 4 presents an overview of the processing steps to radiolabel TiO 2 nanoparticles by the method suggested above.
To implement the process presented in Figure 4 , once the cyclotron production of 45 Ti seems to be feasible, our group looks for optimizing all of the technical aspects. Then, the extraction of 45 Ti from the solid target constitutes a formidable challenge due to pharmaceutical requirements and technical issues, such as the specific activity needed. The task will require, for sure, wet chemistry techniques to fulfill the predefined requisites. The use of radioactive precursors for the labeling of TiO 2 nanoparticles was already mentioned and briefly justified, but special attention should be given to the reduction of preparation time, because the operation is actually very time-consuming. Finally, 45 TiO 2 nanoparticles should be purified, filtered by size, and controlled regarding the surface properties for the appropriate targeting of biological processes.
As a final note, our literature review made on 45 Ti found only one non-oncological application where labeled cations were used for the investigation of cerebral neurodegeneration [46] . biodistribution studies, which can also allow the in vivo monitoring of its biological distribution and the pharmacokinetics of such drug delivery systems. The nanoparticle radiolabeling could be achieved by different methodologies, including activation methods and synthesis based on radioactive precursors [45] . However, apart from other advantages related to the specific activity obtained, synthesis based on radioactive precursors appears to be the simplest and most favorable option, mainly due to the coincidence between the nanoparticle chemical nature (titanium) and the radionuclide that is aimed to be used for radiolabeling ( 45 Ti). Figure 4 presents an overview of the processing steps to radiolabel TiO2 nanoparticles by the method suggested above.
To implement the process presented in Figure 4 , once the cyclotron production of 45 Ti seems to be feasible, our group looks for optimizing all of the technical aspects. Then, the extraction of 45 Ti from the solid target constitutes a formidable challenge due to pharmaceutical requirements and technical issues, such as the specific activity needed. The task will require, for sure, wet chemistry techniques to fulfill the predefined requisites. The use of radioactive precursors for the labeling of TiO2 nanoparticles was already mentioned and briefly justified, but special attention should be given to the reduction of preparation time, because the operation is actually very time-consuming. Finally, 45 TiO2 nanoparticles should be purified, filtered by size, and controlled regarding the surface properties for the appropriate targeting of biological processes.
As a final note, our literature review made on 45 Ti found only one non-oncological application where labeled cations were used for the investigation of cerebral neurodegeneration [46] . 
Conclusion and Future Perspectives
Over the last decades, significant efforts have been made in the fundamental study, testing, development, and optimization of radionuclide production processes. The achievements have benefited the field of medical imaging and, particularly, radionuclide imaging using nuclear medicine methods and techniques. PET presents some advantages that could be used in accordance with the actual paradigms of medicine, in such a way that truthfully modern and personalized medical care could be conducted on patients. The wider use of low-energy cyclotrons is playing a crucial role in increasing the availability of radionuclides for preclinical or clinical trials, diversifying the set of radionuclides available for biomedical applications.
Several unconventional radionuclides for PET are being suggested to be introduced in clinical practice, because of the diversity of pathophysiological processes that could be studied. 55 45 Ti as a reliable candidate for PET imaging, emphasizing again the importance of cyclotrons to provide the production of the radionuclide. The titanium-45 half-life of 3.09 h, together with low energy positrons, were key factors for its selection as an interesting candidate. Potential applications of 45 Ti include some possibilities that have been proposed and briefly studied by other groups, such as imaging with 45 Ti-transferrin to study titanium-based chemotherapy agents or with 45 Ti-salan compounds to be applied in theranostics of cancer. The use of 45 TiO2 nanoparticles here suggested is an innovative proposal that should be developed in the near future. 
Several unconventional radionuclides for PET are being suggested to be introduced in clinical practice, because of the diversity of pathophysiological processes that could be studied. 55 Co, 60/61/64 Cu, 76 Br, 82 Rb, 86 Y, 89 Zr or 124 I represent examples of this trend. This review focused on the exploration of 45 Ti as a reliable candidate for PET imaging, emphasizing again the importance of cyclotrons to provide the production of the radionuclide. The titanium-45 half-life of 3.09 h, together with low energy positrons, were key factors for its selection as an interesting candidate. Potential applications of 45 Ti include some possibilities that have been proposed and briefly studied by other groups, such as imaging with 45 Ti-transferrin to study titanium-based chemotherapy agents or with 45 Ti-salan compounds to be applied in theranostics of cancer. The use of 45 TiO 2 nanoparticles here suggested is an innovative proposal that should be developed in the near future.
